- Home
- NBBK vs VIR Comparison
NBBK vs VIR Comparison
Compare NBBK & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBBK
- VIR
- Stock Information
- Founded
- NBBK 1892
- VIR 2016
- Country
- NBBK United States
- VIR United States
- Employees
- NBBK N/A
- VIR N/A
- Industry
- NBBK
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- NBBK
- VIR Health Care
- Exchange
- NBBK Nasdaq
- VIR Nasdaq
- Market Cap
- NBBK 666.6M
- VIR 724.1M
- IPO Year
- NBBK N/A
- VIR 2019
- Fundamental
- Price
- NBBK $17.25
- VIR $5.97
- Analyst Decision
- NBBK Buy
- VIR Strong Buy
- Analyst Count
- NBBK 1
- VIR 7
- Target Price
- NBBK $22.00
- VIR $33.57
- AVG Volume (30 Days)
- NBBK 239.2K
- VIR 1.2M
- Earning Date
- NBBK 04-22-2025
- VIR 05-01-2025
- Dividend Yield
- NBBK N/A
- VIR N/A
- EPS Growth
- NBBK 421.39
- VIR N/A
- EPS
- NBBK 1.18
- VIR N/A
- Revenue
- NBBK $169,131,000.00
- VIR $74,205,000.00
- Revenue This Year
- NBBK N/A
- VIR N/A
- Revenue Next Year
- NBBK N/A
- VIR $17.69
- P/E Ratio
- NBBK $14.12
- VIR N/A
- Revenue Growth
- NBBK 25.80
- VIR N/A
- 52 Week Low
- NBBK $13.64
- VIR $4.95
- 52 Week High
- NBBK $21.05
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- NBBK 51.40
- VIR 45.21
- Support Level
- NBBK $16.09
- VIR $5.32
- Resistance Level
- NBBK $16.56
- VIR $5.86
- Average True Range (ATR)
- NBBK 0.79
- VIR 0.43
- MACD
- NBBK 0.11
- VIR 0.12
- Stochastic Oscillator
- NBBK 81.48
- VIR 78.83
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.